Apel­lis ex­pects EU to re­ject eye drug; Ter­ray teams up with Bris­tol My­ers; Van­dria rais­es $20M

Plus, news on In­duc­tive Bio, AbelZe­ta Phar­ma, GPCR Ther­a­peu­tics, Bridge Bio­ther­a­peu­tics and NextCure.

Apel­lis pre­empts EU re­jec­tion for eye drug: The com­pa­ny ex­pects a neg­a­tive opin­ion from the Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use on pegc­eta­coplan, which is un­der re­view for the treat­ment of ge­o­graph­ic at­ro­phy sec­ondary to age-re­lat­ed mac­u­lar de­gen­er­a­tion. The com­ple­ment C5 in­hibitor in Feb­ru­ary won US ap­proval for the in­di­ca­tion as Syfovre, but its launch has been plagued by re­al-world safe­ty events. Apel­lis shares $APLS were down 20% on Thurs­day morn­ing. — Ay­isha Shar­ma

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER